Análisis de la acción Immix Biopharma Inc (IMMX)

$7.980

-0.643 (-8.06%)Al cierre

Loading chart…

Máximo: 8.670
Apertura: 8.620
Precio medio ponderado por volumen: 8.20
Volumen: 1.47M
Capitalización: 56.26M
Mínimo: 7.955
Importe: 12.04M
EV/EBITDA, TTM: 0.00

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

immixbio.com

Análisis de IA of Immix Biopharma Inc (IMMX)

Comprar

Immix Biopharma Inc is a good buy right now due to its promising clinical trial results for NXC-201, which showed an 89% complete response rate, and a significant price target increase from analysts, with BofA setting it at $30, indicating over 190% upside potential from the current price of $9.46. However, the stock has experienced a 22.08% decline over the last 20 days, which presents a risk to consider.

Métricas de valoración

El PER previsto actual de Immix Biopharma Inc (IMMX) es 0.00, frente a su media de 5 años de -3.84.

PER previsto

Sobrevalorado

Media 5A P/E

-3.84

P/E actual

0.00

Sobrevalorada

-1.86

Infravalorada

-5.83

EV/EBITDA previsto

Valor razonable

Media 5A EV/EBITDA

-2.48

EV/EBITDA actual

0.00

Sobrevalorada

0.03

Infravalorada

-5.00

Precio/ventas previsto

Valor razonable

Media 5A P/S

7.83

P/S actual

25.33

Sobrevalorada

29.78

Infravalorada

-14.13

Escenarios de precio de Alphio AI para IMMX

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

Alcista

Alcista · 25%IMMX

$3.24

Precio del escenario

Base

Base · 50%IMMX

$2.79

Precio del escenario

Bajista

Bajista · 25%IMMX

$2.22

Precio del escenario

Ballenas con IMMX en cartera

Logos Global Management, L.P.

+ Con en carteraIMMX

-12.29%

Rentabilidad a 3 meses

Deep Track Capital, LP

+ Con en carteraIMMX

-22.28%

Rentabilidad a 3 meses

Cronología de eventos

2026-09-29 (ET)